《东方呼吸联盟》,带您共探精彩病例! 1 病史简介 2 3 4 5 6 关于治疗 李强教授
孙禾 博士、副主任医师、副教授
参考文献: [1]YUNG A P,GRAYSON M L.Psittacosis--a review of 135 cases[J].Med J Aust,1988,148(5):228-233. [2]BURILLO A,BOUZA E.Chlamydophila pneumoniae[J].Infect Dis Clin North Am,2010,24(1):61-71. [3]van BUUREN C E,DORRESTEIN G M,van DIJK J E.Chlamydia psittaci infections in birds:a review on the pathogenesis and histopathological features[J].Vet Q,1994,16(1):38-41. [4]HOGERWERF L,DE GIER B,BAAN B,et al.Chlamydia psittaci(psittacosis)as a cause of community-acquired pneumonia:a systematic review and meta-analysis[J].Epidemiol Infect,2017,145(15):3096-3105. [5]SU S,SU X,ZHOU L,et al.Severe Chlamydia psittaci pneumonia:clinical characteristics and risk factors[J].Ann Palliat Med,2021,10(7):8051-8060. [6]GUO B,WU X,ZHANG Y,et al.Safety and clinical pharmacokinetics of nemonoxacin,a novel non-fluorinated quinolone,in healthy Chinese volunteers following single and multiple oral doses[J].Clin Drug Investig,2012,32(7):475-486. [7]LIN L,CHANG L W,TSAI C Y,et al.Dose escalation study of the safety,tolerability,and pharmacokinetics of nemonoxacin(TG-873870),a novel potent broad-spectrum nonfluorinated quinolone,in healthy volunteers[J].Antimicrob Agents Chemother,2010,54(1):405-410. [8]武晓捷.抗菌新药苹果酸奈诺沙星胶囊群体药代动力学及药代动力学/药效学研究[D].复旦大学,2012. [9]CHENG S L,WU R G,CHUANG Y C,et al.Integrated safety summary of phase II and III studies comparing oral nemonoxacin and levofloxacin in community-acquired pneumonia[J].J Microbiol Immunol Infect,2019,52(5):743-751. [10]ZHAO C,LV Y,LI X,et al.Effects of Nemonoxacin on Thorough ECG QT/QTc Interval:A Randomized,Placebo-and Positive-controlled Crossover Study in Healthy Chinese Adults[J].Clin Ther,2018,40(6):983-992. |
|